Meeting
2020 Genitourinary Cancers Symposium
Novel androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer: A network meta-analysis.
Authors
Amanda Elizabeth Hird
Division of Urology, Sunnybrook Health Sciences Center, University of Toronto, Toronto, ON, Canada
Amanda Elizabeth Hird , Diana E. Magee , Bimal Bhindi , Xiang Y. Ye , Thenappan Chandrasekar , Hanan Goldberg , Laurence Klotz , Neil Fleshner , Raj Satkunasivam , Zachary William Abraham Klaassen , Christopher J.D. Wallis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 131)
Abstract #
131
Poster Bd #
F11
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Network meta-analysis (NMA) comparing the efficacy of enzalutamide versus apalutamide, darolutamide, and bicalutamide for treatment of nonmetastatic (nm) castration-resistant prostate cancer (CRPC).
First Author: Tomasz M. Beer
Poster
2020 Genitourinary Cancers Symposium
A systematic review and network meta-analysis of FDA approved treatment options in men with nonmetastatic, castration-resistant prostate cancer (M0CRPC).
First Author: Irbaz Bin Riaz
Poster
2023 ASCO Annual Meeting
Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR.
First Author: Alicia K. Morgans
Poster
2023 ASCO Genitourinary Cancers Symposium
Real-world use of darolutamide, enzalutamide, and apalutamide for non-metastatic castration-resistant prostate cancer (DEAR).
First Author: Daniel J. George